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azepines with appropriate doses of short-acting or 
intermediate-acting benzodiazepines or zolpidem and to
reduce the number of potentially associated fractures in
a population of elderly New Mexico Medicaid recipients.
METHODS: The New Mexico Medicaid fee-for-service
prescription claims database was reviewed to identify
patients 65 years and older with 2 or more claims for
long-acting benzodiazepines between October 1 and
December 31, 2000. Educational letters, response forms
and prescription proﬁles were mailed to the prescribers,
pharmacies and consultant pharmacists of these patients.
The database was reviewed from March 1 to May 31,
2001 to assess changes in prescribing patterns. Based on
a previous epidemiologic study and Medicare reimburse-
ment for hip fractures, a cost analysis was performed.
RESULTS: A total of 182 patients were included in the
intervention. Educational materials were mailed to 147
prescribers, 94 pharmacies and 12 consultant pharmacists
for these patients on January 31, 2001. Sixty-four pre-
scribers (44%), 30 pharmacies (32%) and 3 consultant
pharmacists (25%) responded for 103 (57%) patients.
Overall, 16% (n = 29) of the remaining eligible patients
were no longer receiving long-acting benzodiazepine
therapy in the 3-month post-intervention period. Based
on a previous epidemiologic study, 3 fractures were
potentially prevented resulting in a cost savings of
$24,256 to Medicaid/Medicare over a period of nine
years.
CONCLUSIONS: A change in patients’ therapy and 
a potential cost savings to the Medicaid/Medicare 
programs was observed after the intervention.
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OBJECTIVES: Between 1994 and 1999, the Food and
Drug Administration approved three new antipsychotic
medications for the treatment of schizophrenia. This
study tracks antipsychotic prescription patterns in the
Department of Veterans Affairs to determine how these
new drugs have diffused in a national healthcare system.
METHODS: Pharmacy claims data were collected for all
patients with a diagnosis of schizophrenia in the Depart-
ment of Veterans Affairs (VA). Patients who were stable
on a pharmacotherapy regimen were followed over ﬁscal
year 2000 to determine how often patients switch to
another drug, how much time elapses before they switch,
the drug to which they switch, and whether they subse-
quently switch back.
RESULTS: Of the 21,873 patients with schizophrenia
who were stable for three months on their medication,
5,426 (24.8%) switched medications during the next 
year. However, half of these patients (2,708 or 49.9%)
switched back to their original therapy, usually within 30
days. Patients stable on clozapine were the least likely 
to switch (17.8%), while patients stable on quetiapine
were the most likely to switch (37.4%). When patients
switched medications, they were most likely to switch 
to olanzapine (35.1%) and least likely to switch to 
clozapine (0.7%) or quetiapine (14.0%).
CONCLUSIONS: Pharmacotherapy for schizophrenia is
a dynamic process. One quarter of patients who are stable
on an antipsychotic drug regimen change their medica-
tion within one year. Quetiapine was the least favored of
the newer drugs. Our results suggest that it is important
that all of these medications are included on formularies.
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The California Medicaid program added olanzapine 
and risperidone to its formulary in October 1997. This
resulted in an immediate but temporary increase in the
total number of patients initiating episodes of therapy
(access effect) and the substitution of second-generation
antipsychotics for older drugs.
OBJECTIVE: Model how the formulary expansion
altered drug selection decisions and then use these models
to match patients for the purpose of estimating the 
cost impact of the formulary expansion. STUDY 
POPULATION: 19,221 olanzapine, 25,252 risperidone
and 1,22,547 patient episodes using traditional drugs
were classiﬁed into three groups: patients with no previ-
ous antipsychotic use (new), patients re-starting drug
therapy and patients switching between antipsychotic
medications without a break in therapy.
METHODS: Multinomial logistic regression models of
the drug selection process were estimated then used to 
calculate propensity scores for olanzapine and risperidone
use using the post-expansion clinical decision criteria.
Health care costs were then compared within quintile bins
for these 3 treatment episode types.
RESULTS: The formulary expansion signiﬁcantly
improved access for minorities, women and urban 
residents. However, the propensity-score matching of
olanzapine and risperidone patients with patients using
traditional antipsychotics (quintile bins) did not result in
highly congruent patient populations. Patients using 
traditional antipsychotics consistently exhibited higher
levels of health care use prior to the start of the treatment
episode. Simple within-bin comparisons of health care
costs found lower costs for olanzapine and risperidone
patients. Differences based on multivariate cost models
within each quintile bin greatly reduced these differences.
However, continuous days of therapy were consistently
higher for risperidone and olanzapine patients.
